CHMP Rejects Serelaxin But Clears Albiglutide, Riociguat And Lurasidone
This article was originally published in The Pink Sheet Daily
Europe’s top medical advisory panel turns down a new acute heart failure therapy from Novartis, but gives positive opinions to three other new active substances, from GlaxoSmithKline, Bayer and Takeda, following its Jan. 20-23 meeting.
You may also be interested in...
Novartis says long-time chairman Daniel Vasella has decided to leave the Swiss drug maker and its board has chosen former COO and current Bayer healthcare division head Jorg Reinhardt to replace him.
Novartis released mixed Phase III data on its heart failure candidate at the American Heart Association Scientific Sessions, showing the drug reduced symptoms of acute heart failure but failed to demonstrate an improvement on a second endpoint, cardiovascular death and hospital stays at 60 days.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.